multiple sclerosis
FDA refuses to review Celgene’s ozanimod in multiple sclerosis
February 28, 2018Research and Development, Sales and Marketing Celgene, FDA, multiple sclerosis, ozanimod, pharma
Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …
Biogen halts Tysabri trial after failure in acute ischemic stroke
February 8, 2018Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure
Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …
Roche’s Ocrevus gets the go ahead in Europe for two forms of MS
January 12, 2018Medical Communications, Sales and Marketing Europe, European Commission, Ocrevus, Roche, multiple sclerosis, pharma
Roche has revealed that its multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has been awarded marketing approval in Europe by the …
NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons
December 20, 2017Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis
NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …
EMA recommends approval of Roche’s Ocrevus in relapsing forms of multiple sclerosis
November 13, 2017Sales and Marketing MS, Ocrevus, Roche, multiple sclerosis, pharma
Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …
NHS England seals access deals with big pharma for breast cancer and MS
November 9, 2017Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …
Breakthrough study could revolutionise MS treatment
October 13, 2017Medical Communications, Research and Development biotech, drugs, multiple sclerosis, pharma, pharmaceutical
The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from …
Roche chalks up Swiss approval for multiple sclerosis drug Ocrevus
September 28, 2017Sales and Marketing Ocrevus, Roche, multiple sclerosis, pharma, pharmaceutical
Roche has announced that its drug Ocrevus (ocrelizumab) has received marketing approval in Switzerland for the treatment of active relapsing …
Novartis celebrates success of Gilenya in paediatric multiple sclerosis
September 5, 2017Manufacturing and Production, Research and Development MS, Novartis, gilenya, health, multiple sclerosis, pharma, pharmaceuticals
Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …
Seven years later, EC gives approval for Merck KGaA’s MS drug
August 25, 2017Medical Communications, Sales and Marketing Mavenclad, Merck KGaA, biotech, drugs, multiple sclerosis, pharma, pharmaceutical
In 2011, Merck KGaA had all but given up on its MS drug after having been knocked back by both …
Novartis launches first large-scale smartphone-based study in multiple sclerosis
August 23, 2017Research and Development MS, Novartis, life sciences, multiple sclerosis, pharma, pharmaceuticals
Novartis has launched what it claims is the first large-scale mobile research study which will gather data on multiple sclerosis …
US Congressmen accuse Teva of price hikes over 1,000%
August 21, 2017Sales and Marketing Copaxone, Teva, life sciences, medicine, multiple sclerosis, pharma, pharmaceutical, price hiking
A pair of US Congressmen have fired allegations at Israeli drugmaker Teva accusing the firm of hiking the price of …
Old antibiotic offers potential cost-effective MS treatment
June 2, 2017Medical Communications, Research and Development Myelin, multiple sclerosis
The cost of treatment for multiple sclerosis varies wildly, in the UK treatment can cost £56,000 per year while in …
Common treatment for MS revealed to have potential adverse reactions
May 16, 2017Manufacturing and Production, Research and Development MS, multiple sclerosis
Beta interferons are a common treatment used to manage multiple sclerosis. The treatment works by reducing and preventing the inflammation …
£6 million statin study to determine potential therapeutic use in MS
May 9, 2017Manufacturing and Production, Research and Development multiple sclerosis, statins
A large study will take place in the UK to determine whether statins, commonly prescribed to combat “bad cholesterol”, are …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEO
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
